Mega licensing deal lifts 3SBio profits but core sales slip
The Chinese drugmaker delivered sharply higher earnings, thanks to a bumper deal with Pfizer to develop a new cancer drug, but its older products came under pressure Key Takeaways: 3SBio’s…
Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
BRIEF: Duality Biotherapies surges in Hong Kong trading debut
Shares of biotech firm Duality Biotherapeutics Inc. (9606.HK) opened up 91% at HK$181 on Tuesday and continued to climb in their Hong Kong trading debut, closing up 127% at HK$214.80…
RELATED ARTICLES
-
3SBio gears up for drugs battle with $400 million equity move
-
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK688331.SHG
-
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK600196.SHG
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Jacobio Pharma poised to turn a profit from precision cancer drugs
